The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 31, 2018
Filed:
Nov. 06, 2015
Applicant:
Novartis Ag, Basel, CH;
Inventors:
Margarita Gekkieva, Basel, CH;
Peter Sallstig, Fort Worth, TX (US);
Werner Schmidt, Fort Worth, TX (US);
James Warburton, Basel, CH;
Andreas Weichselberger, Basel, CH;
Assignee:
Novartis Pharma AG, Basel, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/22 (2006.01); A61B 3/12 (2006.01); A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61B 5/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/22 (2013.01); A61B 3/12 (2013.01); A61B 5/4848 (2013.01); A61K 9/0048 (2013.01); A61K 39/3955 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01);
Abstract
A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.